Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

BACKGROUND: ZyCoV-D, a DNA-based vaccine, showed promising safety and immunogenicity in a phase 1/2 trial. We now report the interim efficacy results of phase 3 clinical trial with ZyCoV-D vaccine in India. METHODS: We conducted an interim analysis of a multicentre, double-blind, randomised, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Khobragade, Akash, Bhate, Suresh, Ramaiah, Vijendra, Deshpande, Shrikant, Giri, Krishna, Phophle, Himanshu, Supe, Pravin, Godara, Inderjeet, Revanna, Ramesh, Nagarkar, Rajnish, Sanmukhani, Jayesh, Dey, Ayan, Rajanathan, T M Chozhavel, Kansagra, Kevinkumar, Koradia, Parshottam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970574/
https://www.ncbi.nlm.nih.gov/pubmed/35367003
http://dx.doi.org/10.1016/S0140-6736(22)00151-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970574/
https://www.ncbi.nlm.nih.gov/pubmed/35367003
http://dx.doi.org/10.1016/S0140-6736(22)00151-9

Ejemplares similares